Eisai China Inc. is a pharmaceutical company wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. Eisai has been smoothly developing its business in China since the early 1990s, starting with the establishment of Shenyang Eisai Pharmaceutical Co., Ltd. in 1991 followed by the establishment of Eisai Suzhou Pharmaceutical Co. in Suzhou Industrial Park, a pharmaceutical manufacturing facility which was officially renamed Eisai China Inc. in 2002. Eisai China Inc. completed the construction of its injection plant in Nov. 2014, and purchased a Chinese generic drug manufacturer to establish Eisai (Liaoning) Pharmaceutical Co., Ltd. in Nov. 2015. In May 2016, Eisai China Inc. held a groundbreaking ceremony of its new solid preparation plant. Currently, Eisai China Inc. promotes more than 10 pharmaceutical brands in China, specializing in the Central Nervous System, Digestive System, Endocrine and Orthopedic areas. It became the No.1 Japanese pharmaceutical company in China in terms of saleroom in 2015.